



HAL
open science

A 10-year retrospective comparison of two target sequences, REP-529 and B1, for *Toxoplasma gondii* detection by quantitative PCR

Sorya Belaz, Jean-Pierre Gangneux, Peggy Dupretz, Claude Guiguen, Florence Robert-Gangneux

► To cite this version:

Sorya Belaz, Jean-Pierre Gangneux, Peggy Dupretz, Claude Guiguen, Florence Robert-Gangneux. A 10-year retrospective comparison of two target sequences, REP-529 and B1, for *Toxoplasma gondii* detection by quantitative PCR. *Journal of Clinical Microbiology*, 2015, 53 (4), pp.1294-1300. 10.1128/JCM.02900-14 . hal-01118293

HAL Id: hal-01118293

<https://univ-rennes.hal.science/hal-01118293>

Submitted on 28 Apr 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **A 10-year retrospective comparison of two target sequences, REP-529 and B1, for *Toxoplasma***
2 ***gondii* detection by quantitative PCR**

3

4 **Running title:** REP-529 in clinical diagnosis

5

6 Sorya BELAZ ^{1,2}, Jean-Pierre GANGNEUX ^{1,2}, Peggy DUPRETZ ², Claude GUIGUEN ², Florence ROBERT-
7 GANGNEUX ^{1,2}

8

9 ¹ INSERM U1085, Institut de Recherche en Santé Environnement et Travail, Université Rennes 1,
10 Rennes, France.

11 ² Laboratoire de Parasitologie et Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes,
12 France.

13

14 Corresponding author:

15 Florence Robert-Gangneux, Centre hospitalier et universitaire de Rennes, 2 rue Henri le Guilloux,
16 35033 Rennes Cedex, France

17 Florence.robert-gangneux@univ-rennes1.fr

18

19 **Key-points (40 words):** Few studies analyzed the impact of the lower sensitivity of B1-based
20 quantitative PCR (qPCR) for the molecular diagnosis of toxoplasmosis. Our results show that B1 qPCR
21 amplified only 54.4% of REP-529-positive clinical samples prospectively obtained from patients with
22 toxoplasmosis.

23

24

25 **Key words:** diagnosis, toxoplasmosis, qPCR, Toxoplasma B1, Toxoplasma REP-529

26

27 **Abstract**

28

29 This study aimed to evaluate the repeated sequence REP-529 compared to the B1 gene for the
30 molecular diagnosis of toxoplasmosis by quantitative PCR (qPCR) in routine diagnosis.

31 Over a ten-year period (2003-2013), all patients prospectively diagnosed with a positive REP-529
32 qPCR result for toxoplasmosis were included. All DNA samples (76 samples from 56 patients) were
33 simultaneously tested using the two qPCR methods (REP-529 and B1).

34 The mean Ct obtained with the B1 qPCR was significantly higher (+4.71 cycles) than that obtained
35 with REP-529 qPCR ($p < 0.0001$). Thirty-one out of 69 extracts (45.6%) positive with REP-529 qPCR
36 were not amplified with the B1 qPCR (relative sensitivity 54.4%, compared to REP-529), yielding false
37 negative results on 15/28 placentas, 5 cord blood, 2 amniotic fluids, 4 cerebrospinal fluids, 1 aqueous
38 humor, 2 lymph node punctures and 1 abortion product. This defect in sensitivity would have left
39 20/56 patients undiagnosed, distributed as follows: 12/40 congenital toxoplasmosis, 4/5 cerebral
40 toxoplasmosis, 2/8 patients with retinochoroiditis, and both patients with chronic lymphadenopathy.

41 This poor performance of B1 qPCR could be related to low parasite loads, since the mean
42 *Toxoplasma* quantification in extracts with B1 false negative results was 0.4 parasite/reaction.

43 These results clearly show the superiority of the REP-529 sequence in the diagnosis of toxoplasmosis
44 by PCR suggest that this target should be adopted as part of standardization of the PCR assay.

45

46

47 **Introduction**

48

49 Toxoplasmosis is a worldwide parasitic infection due to the intracellular parasite *Toxoplasma gondii*.
50 The infection is usually asymptomatic in immunocompetent patients, and more rarely result in fever,
51 lymphadenopathy or retinochoroiditis. By contrast, immunocompromised patients can experiment
52 severe neurologic, ocular, pulmonary or disseminated disease (1). Yet toxoplasmosis is well-known
53 for its pathogenicity during pregnancy. Indeed, when primary infection occurs in pregnant women, it
54 can lead to congenital toxoplasmosis, with a frequency of transmission and a severity of fetal
55 infection depending on the stage of pregnancy at which infection occurs (2). Diagnosis of
56 toxoplasmosis is routinely based on serology. In some countries, such as France, seronegative
57 pregnant women are monitored monthly by serology. In case of seroconversion, detection of
58 *Toxoplasma gondii* DNA by PCR is a major diagnostic method for congenital toxoplasmosis, and is
59 performed on amniotic fluid (prenatal diagnosis)(3-5), and placenta or cord blood at birth (postnatal
60 diagnosis)(6-8). In immunocompromised patients, DNA can also be found in cerebro-spinal fluid
61 (CSF), broncho-alveolar lavage (BAL) or others samples guided by clinical signs. The 35-fold repeated
62 B1 gene (9) has been commonly used for this molecular diagnosis since 1989 with acceptable
63 sensitivity (3, 5, 10), but another sequence (REP-529, Genbank AF146527) was described more
64 recently, as being 200- to 300-fold repeated (11), leading to better detection of low parasite loads
65 using spiked specimens (12). Our objective was to evaluate the diagnostic gain resulting from the
66 routine use of a quantitative PCR (qPCR) targeting REP-529, compared to a qPCR targeting the B1
67 gene, for the diagnosis of toxoplasmosis in various clinical settings. In this study, we analyzed
68 retrospectively the qPCRs results of all *T. gondii*-positive DNA samples from patients who benefited
69 from molecular diagnosis over a 10-year period.

70

71 **Materials and methods**

72

73 Patients and sample collection

74 During the study period (2003-2013), all patients with a diagnosis of congenital toxoplasmosis who
75 benefited from a molecular diagnosis on at least one sample (amniotic fluid, placenta or cord blood)
76 were included. Congenital toxoplasmosis was defined by a positive prenatal diagnosis for
77 *Toxoplasma gondii* (molecular diagnosis and/or mouse inoculation) and/or serologic evidence of
78 antibody synthesis by the newborn at birth or during the one-year serologic monitoring (specific IgM
79 or IgA detected by ISAGA (BioMérieux, Marcy-l'Etoile, France) or neosynthesized IgG detected by
80 western-blot (LD-Bio, Lyon, France)). During the study period, routine qPCR molecular diagnosis

81 relied on both gene targets (B1 and REP-529) from 2003-2005, then only REP-529 has been used until
82 now. All positive samples were re-analyzed with both gene targets in the same qPCR run, to
83 homogenize parasite quantification, as standard curve had changed meanwhile. Additionally, all
84 samples from proven congenitally infected infants which had been tested negative in routine
85 diagnosis with REP-529 were also retested in parallel with the B1 PCR.
86 Besides, adult patients with clinical signs compatible with toxoplasmosis (lymph nodes with specific
87 anti-*Toxoplasma* IgM, uveitis, retinochoroiditis, cerebral abscess) and a positive DNA detection with
88 REP-529 from 2009-2013 were also included, and DNA samples were re-analyzed with both qPCRs.

89

90 Molecular diagnosis

91 On reception of the placenta (PL), several samples were taken from different sites and mixed in a
92 solution containing 2.5 mg/mL trypsin, penicillin 500 IU/mL, and gentamicin 3.3µg/mL. The
93 preparation was digested for 2 hours at 37°C under agitation, filtered through gauze and centrifuged
94 for 10 minutes at 1000 g. The supernatant was discarded and the pellet was washed 3 times. Then,
95 200µl of prepared placentas and other crushed biopsies (lymph-node or cerebral) were digested
96 overnight with proteinase K at 56°C prior to extraction. Amniotic fluids (AF) samples (10mL) were
97 centrifuged at 1500xg for 10 min then supernatant was discarded and 2x200µL samples of the pellet
98 were used for DNA extraction. Other fluids (CSF, aqueous humor (AH)) were centrifuged at 1500xg
99 for 10 min, and 200µL of pellet was used for DNA extraction. Routinely, DNA extraction of all samples
100 was performed using QIAamp DNA mini kit® columns (Qiagen, Courtaboeuf, France) and eluted in
101 100µL, except for blood (peripheral blood (PB) and cord blood (CB)) samples, which were processed
102 using 1-2 mL of whole blood and extracted using QIAamp DNA midi kit® columns (Qiagen), and
103 eluted in 400 µL. Two extracts were performed for amniotic fluids and placentas (only one for other
104 samples) and amplification was run in duplicate for all samples.

105 The primers and probe used to amplify a 98 pb fragment of the B1 gene were 5'-GAA AGC CAT GAG
106 GCA CTC CA-3' (forward) and 5' -TTC ACC CGG ACC GTT TAG C- 3' (reverse), and FAM™-5'-CGG GCG
107 AGT AGC ACC TGA GGA GAT ACA-3'-TAMRA™ (13), and primers and probe targeting REP-529 were
108 those described previously (6). All samples were re-analyzed by both qPCRs in the same run, using
109 the following conditions: 25µl reaction mixture containing primers and probe at a final concentration
110 of 600 nM and 200 nM, respectively, 12.5 µL of TaqMan™ Universal PCR Master mix (Applied
111 Biosystems, Courtaboeuf, France), and 5 µL of DNA sample. Amplification was performed on a Step
112 One plus device (Applied Biosystems) for 40 cycles (15 sec 95°C and 1 min 60°C) preceded by 10 min
113 at 55°C for UNG reaction and 10 min denaturation at 95°C. Appropriate controls were included in
114 each run (positive and negative controls, internal control of inhibition). Positive samples were

115 quantified using standard curve obtained by serial dilutions of a standardized control (10^5
116 *Toxoplasma* RH strain), provided by the National Reference Center for Toxoplasmosis. In the aim to
117 compare quantification data over the study period, all positive samples were re-analyzed for
118 quantification using the same standard curve. The cycle threshold (Ct) of positive samples was
119 recorded for comparison of REP-529 and B1 qPCRs. All Ct results previously acquired during routine
120 analysis and results acquired after retesting for parasite quantification for the purpose of this study
121 were compared to ensure that long storage did not alter DNA.

122

123 Statistical analysis

124 Before comparing the sensitivity of REP-529 and B1 targets, we verified the quality of DNA samples
125 stored at -20°C , by using a Wilcoxon paired test to compare the Ct newly obtained with REP-529
126 qPCR to the Ct previously recorded in routine diagnosis.

127 For the statistical analysis of relative sensitivity between B1 and REP-529 qPCRs, paired Ct obtained
128 with both qPCRs were compared using the Wilcoxon test. The mean Ct obtained with B1 or REP-529
129 qPCR per type of sample were also compared using the Mann-Whitney test. Only newly acquired
130 quantitative results obtained with both PCR simultaneously were taken into account for statistical
131 analysis. Absolute sensitivity of each PCR for the diagnosis of congenital toxoplasmosis was evaluated
132 on the whole cohort of congenitally infected infants diagnosed over the study period who benefited
133 either from prenatal diagnosis or neonatal diagnosis by PCR.

134 Statistical analysis was made using GraphPad® Prism V5 (GraphPad software, USA). $P < 0.05$ was
135 considered significant.

136

137 **Results**

138

139 Patients and samples

140 Forty-one cases of congenital toxoplasmosis were included, consisting of 20 amniotic fluids, 1
141 abortion product, 35 placentas and 5 cord blood samples. Additionally, 7 cases of reactivation
142 toxoplasmosis in immunocompromised patients (2 blood samples, 4 CSF, 1 vitreous fluid and 1
143 cerebral biopsy) and 7 cases of symptomatic toxoplasmosis in immunocompetent patients were
144 included (2 lymph node biopsy specimens, 5 aqueous humors). Overall, 76 samples from 56 patients
145 were analyzed. Clinical and biological data of the patients are detailed in Table 1.

146

147 Lack of impact of storage on qPCR Ct

148 Forty-nine samples were retrospectively re-analyzed with B1 qPCR in this work, thus it was essential
149 to verify that long-term storage at -20°C after initial diagnosis had not altered DNA. The mean Ct of
150 REP-529 qPCR obtained on samples before (at time of diagnosis) and after storage were similar (31.9
151 \pm 0.8 versus 32.1 \pm 0.8, $p=0.8347$). Additionally, the Ct results were compared using a Wilcoxon
152 paired test, which confirmed that they did not differ ($p = 0.1631$, data not shown), thus making
153 possible the interpretation of the data.

154

155 Comparison of B1 qPCR vs REP529 qPCR

156 The performance of both qPCR targets was analyzed on 76 samples. Overall, 31 of 69 extracts (45%)
157 tested positive with REP-529 qPCR were not amplified by the B1 qPCR, thus the relative sensitivity of
158 the B1 qPCR was 55%, compared to the REP-529 qPCR (Table 2). Seven false negative results (7
159 placenta samples) were also observed with REP-529; none was positive with the B1 qPCR. Thus, over
160 the study period, the absolute sensitivity of REP-529 qPCR and B1 qPCR on placenta samples was
161 80% and 37%, respectively (Tables 1&3). Their absolute specificity for prenatal diagnosis was 100%
162 and 90%, respectively (Table 3). False negative results with the B1 qPCR, compared to REP-529 qPCR,
163 were observed on all sample types, yet mainly on placenta samples (15/28, 54%), blood samples
164 (6/7, 86%), and CSF (4/4, 100%) (Table 2). Overall, the mean Ct obtained with REP-529 qPCR when B1
165 qPCR was negative was 36.84 \pm 0.36 (corresponding to 0.37 \pm 0.3 parasites/reaction), underlining the
166 need for a very sensitive qPCR assay. For the 38 samples which could be amplified with both qPCRs,
167 the mean Ct obtained with the B1 qPCR was significantly higher (+4.7 \pm 0.3 Ct) than that obtained
168 with REP-529 qPCR ($p<0.001$) (Table 4). The mean gain in amplification Ct ranged from 3.65 to 4.98
169 according to the type of sample, and was highly significant for amniotic fluids and placenta samples
170 ($p<0.001$, Table 4). The difference was not statistically significant for aqueous humor samples,
171 probably because of a lack of statistical power.

172 Regarding congenital toxoplasmosis, the B1 qPCR failed to amplify any of the available samples (AF,
173 PL or CB) in 11 out of 40 cases (27.5%) which were positive with REP-529 qPCR. This defect in
174 sensitivity would have had variable consequences according to the results of other biological
175 techniques used. Importantly, prenatal diagnosis would have been falsely negative in two cases (#19
176 and 31), and fetal infection would have remained unproven in a case of fetal loss (#17). Of note, B1
177 target also yielded a false negative result on the placenta sample from case #19 (Table 1). In three
178 other cases (#20, 26, 27), where no prenatal diagnosis had been performed because of late maternal
179 infection during the third trimester of pregnancy, the B1 qPCR would have left the newborns
180 undiagnosed, since no serological evidence of infection was observed until several months (Table 1).
181 For the five remaining cases (#8, 11, 15, 22, 30), the consequences of the reduced sensitivity of B1

182 qPCR would have been negligible, as serological markers of congenital infection (specific IgM or IgA
183 detection, neosynthesized IgG on western-blot) were observed in newborns at birth or during the
184 first week of live. In case #15, B1 qPCR was falsely negative in both placenta and cord blood. In the
185 remaining cases, the lack of sensitivity of B1 on placenta samples was moot, since the diagnosis had
186 been made previously on AF.

187 Regarding ocular toxoplasmosis, one aqueous humor from an immunocompetent patient for whom
188 Western blot was not contributive, and one blood sample from a HIV+ patient, who did not undergo
189 aqueous humor puncture (Table 1), were negative with B1, which would have left 2 patients
190 undiagnosed. Additionally, the B1 target would have left undiagnosed 4 out of 5 (80%) cerebral
191 toxoplasmosis, and the two patients with chronic lymphadenopathy (Table 2).

192

193 **Discussion**

194

195 This study including all positive samples obtained by REP-529 qPCR over a 10-year period, clearly
196 shows the superiority of the REP-529 target for the diagnosis of toxoplasmosis, whatever the clinical
197 setting. As previously described in other studies, this can be explained by the difference in the
198 number of repetitions of this sequence (about 7- to 10 fold more repeated than B1)(11), which
199 results in a gain of about 4 C_t (12, 14), as observed here (p<0.001), and allows detection of 10-fold
200 lower parasite loads (14). However, few studies evaluated the impact in terms of sensitivity of
201 diagnosis in routine clinical use.

202 Filisetti et al. (15) compared three PCR methods on 23 selected AF samples and 16 CB from 19 cases
203 of congenital toxoplasmosis, and found that only 5 out of 9 REP-529-positive AF were positive with
204 the B1 PCR. It must be noted that the overall sensitivity in this study was very low, since only 11 out
205 of 19 AF (58%) were positive with the reference method used, i.e. rDNA PCR (16), which could be due
206 to the use of conventional PCR methods in this study. Cassaing et al. (14) included 33 positives
207 samples (8 AF, 15 PL, 3 AH, 3 CSF, 2 blood samples and 2 BAL), of which 13/15 (87%) PL and 8/8 AF
208 (100%) tested positive with REP-529 qPCR were also positive with B1 qPCR. No differences in
209 sensitivity between both targets were observed for AH, CSF and BAL samples, but all samples were
210 tested in duplicate and in 11 instances, negative results were observed in 1 of the 2 amplifications
211 with B1 qPCR, whereas one sample was amplified by REP-529 qPCR only once. Additionally, the
212 authors considered a B1 result as positive, although it was over 40 Ct, in 4 samples. Another study
213 (17) included prospectively 135 AF samples, of which 27 and 22 were positive with REP-529 and B1
214 qPCR, respectively. The authors declared that 2 of the 5 presumed false negative B1 results were in
215 fact false positive REP-529 results, however, no details are provided on the newborns follow-up and

216 the criteria that led them to this conclusion. Finally, the most recent study (18) evaluated three qPCR
217 methods, mainly on AF samples. The authors reported 33 positive results with their B1 qPCR,
218 compared to 43 with two REP-529 qPCR methods, leading to a relative sensitivity of 77% for B1. Two
219 cord blood samples tested positive with REP-529 were negative with B1 qPCR. Additionally, they
220 found that their two REP-529 qPCRs methods and devices (Applied Biosystem and Roche) performed
221 equally.

222 Our study focused on the evaluation of the relative sensitivity of B1 versus REP-529 PCR targets, thus
223 all PCR-positive samples were included. Additionally, all samples (AF, PL) from congenitally infected
224 children with a negative REP-529 qPCR result were retested. No samples with B1-positive and REP-
225 529-negative results were observed, either prospectively or retrospectively, in cases of proven
226 congenital toxoplasmosis. The overall relative sensitivity of the B1 qPCR was only 55%, and its
227 absolute sensitivity was 37% in the setting of congenital toxoplasmosis (Tables 2&3). This defect in
228 sensitivity was particularly crucial for 3 antenatal diagnoses (2 prenatal diagnoses and 1 early fetal
229 loss undiagnosed) and 3 neonatal diagnoses. In case of fetal loss, the recognition of the role of
230 *Toxoplasma* is important, because it allows to eliminate other causes of spontaneous abortion and
231 avoids useless investigations. On the other hand, the positivity of prenatal diagnosis usually leads to
232 a change in chemotherapy, using pyrimethamine-sulfonamide combination therapy to treat the
233 mother (1-2), which would have been missed in the two B1-negative patients here. Finally, the
234 parasite DNA detection in placenta, even if not yet recognized as a standard criteria for the diagnosis
235 of congenital toxoplasmosis, was shown to have a positive predictive value over 90% in our hands
236 (6), and is at least a strong argument to accurately follow the infant and increase the frequency of
237 serologic testing to confirm infection, with the aim of reducing delay of treatment. We observed here
238 that parasite DNA detection from placenta was the earliest biological sign of infection in neonates
239 with neither IgM nor IgA detection, and recall the interest of this sample in patients for whom
240 antenatal diagnosis was negative or not performed. In 2 cases (#23, 41), both qPCR were negative on
241 placenta samples, whereas they were positive with mouse inoculation, still underlining the interest
242 to combine both techniques (Table 1).

243 The B1 qPCR had also poor sensitivity in other clinical settings. The diagnosis of cerebral
244 toxoplasmosis is difficult, and ancient studies have reported a poor sensitivity of conventional PCR
245 methods (19-20), probably related to low parasite loads, but no recent studies evaluated new qPCR
246 methods in this setting. The present study was not designed to answer this question, but we noted
247 that four patients would have been undiagnosed using B1 qPCR. Besides, the REP-529 qPCR allowed
248 diagnosing two cases of chronic toxoplasmosis in patients with lymphadenopathy and history of

249 *Toxoplasma* seroconversion in the past twelve months, which led to consider this diagnosis and stop
250 further exploration aiming at diagnosing a hematological malignancy.

251 False negative results targeting B1 had a $C_t > 34$ (mean 36.84 ± 0.36). This poor performance of B1
252 qPCR could be related to low parasite loads, a frequently observed situation in congenital
253 toxoplasmosis, particularly in France where women are treated all along pregnancy, which probably
254 decreases the parasite burden. In the study by Romand et al. (21), 88 positive AF were included, of
255 which 35 (40%) were shown to contain less than 10 parasite/mL.

256 Besides, the proportion of undetected samples with the B1 qPCR was high for placenta samples (57%
257 of REP-529-positive samples) and blood samples (50%). In 12 placenta samples, B1 qPCR was
258 negative whereas mouse inoculation was positive, which is unusual. Poor sensitivity on blood and
259 placenta samples suggests that inhibitors would more likely interfere with this PCR. Indeed, Chabbert
260 et al. (22) nicely showed that the efficacy of PCR on samples spiked with low amounts of parasites
261 was lower in placenta or blood, compared to AF, with both sets of B1 primers used.

262 After the description of the REP-529 sequence, the B1 target has been still frequently used in parallel
263 in most labs, including ours, until it could be demonstrated that the occurrence of B1 positive results
264 and REP-529 negative results was never observed (14-15, 18), suggesting that this sequence is
265 present in all parasite isolates. However, a recent Brazilian study (23) reported a lower proportion of
266 positive amniotic fluids with REP-529 target, than with B1 (36.5% and 87.3%, respectively), with only
267 23.8% of samples being positive with both targets. This unusual finding must be verified on other
268 series of clinical samples from South America, to check if atypical parasite strains circulating in this
269 area could lack the REP-529 sequence or have mutations or modification of the number of
270 repetitions, that could lead to a decreased sensitivity of this PCR target, which now appears to be the
271 gold standard for European parasite strains.

272 Therefore, in view of the results obtained in the present study, we suggest widespread use of the
273 REP-529 qPCR target, which should replace B1 target, at least in Western countries, until its value is
274 confirmed in South America.

275

276 REFERENCES

- 277 1. **Montoya JG, Liesenfeld O.** 2004. Toxoplasmosis. *Lancet* **363**:1965-1976.
- 278 2. **Robert-Gangneux F, Darde ML.** 2012. Epidemiology of and diagnostic strategies for
279 toxoplasmosis. *Clin Microbiol Rev* **25**:264-296.
- 280 3. **Robert-Gangneux F, Gavinet MF, Ancelle T, Raymond J, Tourte-Schaefer C, Dupouy-Camet**
281 **J.** 1999. Value of prenatal diagnosis and early postnatal diagnosis of congenital
282 toxoplasmosis: retrospective study of 110 cases. *J Clin Microbiol* **37**:2893-2898.
- 283 4. **Romand S, Wallon M, Franck J, Thulliez P, Peyron F, Dumon H.** 2001. Prenatal diagnosis
284 using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. *Obstet*
285 *Gynecol* **97**:296-300.
- 286 5. **Sterkers Y, Pratlong F, Albaba S, Loubersac J, Picot MC, Pretet V, Issert E, Boulot P, Bastien**
287 **P.** 2012. Novel interpretation of molecular diagnosis of congenital toxoplasmosis according
288 to gestational age at the time of maternal infection. *J Clin Microbiol* **50**:3944-3951.
- 289 6. **Robert-Gangneux F, Dupretz P, Yvenou C, Quinio D, Poulain P, Guiguen C, Gangneux JP.**
290 2010. Clinical relevance of placenta examination for the diagnosis of congenital
291 toxoplasmosis. *Pediatr Infect Dis J* **29**:33-38.
- 292 7. **Fricker-Hidalgo H, Brenier-Pinchart MP, Schaal JP, Equy V, Bost-Bru C, Pelloux H.** 2007.
293 Value of *Toxoplasma gondii* detection in one hundred thirty-three placentas for the diagnosis
294 of congenital toxoplasmosis. *Pediatr Infect Dis J* **26**:845-846.
- 295 8. **Sterkers Y, Ribot J, Albaba S, Issert E, Bastien P, Pratlong F.** 2011. Diagnosis of congenital
296 toxoplasmosis by polymerase chain reaction on neonatal peripheral blood. *Diagn Microbiol*
297 *Infect Dis* **71**:174-176.
- 298 9. **Burg JL, Grover CM, Pouletty P, Boothroyd JC.** 1989. Direct and sensitive detection of a
299 pathogenic protozoan, *Toxoplasma gondii*, by polymerase chain reaction. *J Clin Microbiol*
300 **27**:1787-1792.
- 301 10. **Teixeira LE, Kanunfre KA, Shimokawa PT, Targa LS, Rodrigues JC, Domingues W, Yamamoto**
302 **L, Okay TS.** 2013. The performance of four molecular methods for the laboratory diagnosis of
303 congenital toxoplasmosis in amniotic fluid samples. *Rev Soc Bras Med Trop* **46**:584-588.
- 304 11. **Homan WL, Vercammen M, De Braekeleer J, Verschuieren H.** 2000. Identification of a 200-
305 to 300-fold repetitive 529 bp DNA fragment in *Toxoplasma gondii*, and its use for diagnostic
306 and quantitative PCR. *Int J Parasitol* **30**:69-75.
- 307 12. **Reischl U, Bretagne S, Kruger D, Ernault P, Costa JM.** 2003. Comparison of two DNA targets
308 for the diagnosis of Toxoplasmosis by real-time PCR using fluorescence resonance energy
309 transfer hybridization probes. *BMC Infect Dis* **3**:7.
- 310 13. **Fekkar A, Bodaghi B, Touafek F, Le Hoang P, Mazier D, Paris L.** 2008. Comparison of
311 immunoblotting, calculation of the Goldmann-Witmer coefficient, and real-time PCR using

- 312 aqueous humor samples for diagnosis of ocular toxoplasmosis. *J Clin Microbiol* **46**:1965-
313 1967.
- 314 14. **Cassaing S, Bessieres MH, Berry A, Berrebi A, Fabre R, Magnaval JF.** 2006. Comparison
315 between two amplification sets for molecular diagnosis of toxoplasmosis by real-time PCR. *J*
316 *Clin Microbiol* **44**:720-724.
- 317 15. **Filisetti D, Gorcii M, Pernot-Marino E, Villard O, Candolfi E.** 2003. Diagnosis of congenital
318 toxoplasmosis: comparison of targets for detection of *Toxoplasma gondii* by PCR. *J Clin*
319 *Microbiol* **41**:4826-4828.
- 320 16. **Cazenave J, Cheyrou A, Begueret J.** 1993. Improvement of rDNA-based PCR assay to detect
321 *Toxoplasma*. *Prenat Diagn* **13**:543.
- 322 17. **Kasper DC, Sadeghi K, Prusa AR, Reischer GH, Kratochwill K, Forster-Waldl E, Gerstl N,**
323 **Hayde M, Pollak A, Herkner KR.** 2009. Quantitative real-time polymerase chain reaction for
324 the accurate detection of *Toxoplasma gondii* in amniotic fluid. *Diagn Microbiol Infect Dis*
325 **63**:10-15.
- 326 18. **Delhaes L, Yera H, Ache S, Tsatsaris V, Houfflin-Debarge V.** 2013. Contribution of molecular
327 diagnosis to congenital toxoplasmosis. *Diagn Microbiol Infect Dis* **76**:244-247.
- 328 19. **Robert F, Ouatas T, Blanche P, Tourte-Schaefer C, Sicard D, Dupouy-Camet J.** 1996.
329 [Retrospective evaluation of the detection of *Toxoplasma gondii* by polymerase chain
330 reaction in AIDS patients]. *Presse Med* **25**:541-545.
- 331 20. **Bastien P.** 2002. Molecular diagnosis of toxoplasmosis. *Trans R Soc Trop Med Hyg* **96 Suppl**
332 **1**:S205-215.
- 333 21. **Romand S, Chosson M, Franck J, Wallon M, Kieffer F, Kaiser K, Dumon H, Peyron F, Thulliez**
334 **P, Picot S.** 2004. Usefulness of quantitative polymerase chain reaction in amniotic fluid as
335 early prognostic marker of fetal infection with *Toxoplasma gondii*. *Am J Obstet Gynecol*
336 **190**:797-802.
- 337 22. **Chabbert E, Lachaud L, Crobu L, Bastien P.** 2004. Comparison of two widely used PCR primer
338 systems for detection of toxoplasma in amniotic fluid, blood, and tissues. *J Clin Microbiol*
339 **42**:1719-1722.
- 340 23. **Okay TS, Yamamoto L, Oliveira LC, Manuli ER, Andrade Junior HF, Del Negro GM.** 2009.
341 Significant performance variation among PCR systems in diagnosing congenital toxoplasmosis
342 in Sao Paulo, Brazil: analysis of 467 amniotic fluid samples. *Clinics (Sao Paulo)* **64**:171-176.

343

344 Table 1: Clinical characteristics and qPCR results for 41 mother-child pairs of congenital toxoplasmosis, 8 cases of ocular toxoplasmosis, 5 cases of cerebral
 345 toxoplasmosis and 2 cases of chronic lymphadenopathy

346

347

Case N°	Clinical setting	Clinical signs (Pregnancy trimester at maternal infection for CoT)	Sample	qPCR results		Mouse inoculation	Other biological criteria of infection
				B1	Rep-529		
1	CoT	Abnormal neurodevelopment (ultrasound) : Medical termination of pregnancy (T1)	AF	+	+	+	Positive qPCR (REP) on fetal biopsy
			PL	+	+	ND	
2	CoT	Asymptomatic (T3)	AF	+	+	+	IgM detection at 3month in the infant (in another hospital), PL positive by mouse inoculation
3	CoT	Asymptomatic (T3)	PL	+	+	+	Positive prenatal diagnostic in another hospital. Neosynthesized IgG/IgM by WB; IgM and IgA detection at birth
			CB	-	+	ND	
4	CoT	Asymptomatic (T3)	PL	+	+	ND	Neosynthesized IgG/IgM by WB; IgM and IgA detection at 1 month
			CB	-	+	ND	
5	CoT	Asymptomatic (T3)	PL	+	+	+	IgM at birth
6	CoT	Asymptomatic (T2)	AF	+	+	-	Persisting IgG at 1 year of life
			PL	-	+	+	
7	CoT	Ventriculomegaly (ultrasound) : Medical termination of pregnancy (T1)	PL	+	+	+	<i>Toxoplasma</i> detection in AF by mouse inoculation
8	CoT	Asymptomatic (T3)	PL	-	+	+	Neosynthesized IgG/IgM by WB; IgM and IgA detection at birth
9	CoT	Intracerebral calcifications (ultrasound) (T2-3)	AF	+	+	+	Persisting IgG at 1 year of life, <i>Toxoplasma</i> detection in PL by mouse inoculation
10	CoT	Asymptomatic (T2)	PL	+	+	+	Neosynthesized IgG by WB
11	CoT	Seizure after birth (T3)	PL	-	+	+	Positive prenatal diagnostic in another hospital,

							neosynthesized IgM (WB) at birth
12	CoT	Unknown (T3)	PL	+	+	+	Neosynthesized IgG/IgM by WB
13	CoT	Intrauterine fetal death (T2)	AF	+	+	+	
14	CoT	Asymptomatic (T3)	AF	+	+	+	Neosynthesized IgG/IgM, IgM and IgA detection at birth
			PL	-	+	+	
15	CoT	Asymptomatic (T3)	PL	-	+	-	IgM and IgA detection at 1 week of life
			CB	-	+	ND	
16	CoT	Unknown (T3)	PL	+	+	+	Neosynthesized IgG/IgM by WB; IgM and IgA detection at birth
			CB	-	+	ND	
17	CoT	Termination of pregnancy (T1)	AP	-	+	ND	
18	CoT	Chorioretinitis (T2)	AF	+	+	+	IgM detection at birth
			PL	-	-	-	
19	Co T	Asymptomatic (T3)	AF	-	+	+	Neosynthesized IgG/IgM by WB; IgM and IgA detection at birth
			PL	-	+	+	
20	CoT	Asymptomatic (T3)	PL	-	+	+	IgM (in another hospital) at birth
21	CoT	Asymptomatic (T3)	AF	+	+	+	Neosynthesized IgG/IgM by WB at birth
22	CoT	Asymptomatic (T3)	PL	-	+	+	Positive prenatal diagnostic in another hospital
23	CoT	Asymptomatic (T2)	AF	+	+	+	Neosynthesized IgG/IgM by WB; IgM and IgA detection at birth
			PL	-	-	+	
24	CoT	Chorioretinitis (T2)	AF	+	+	+	IgM and IgA detection at birth and neosynthesized IgG/IgM by WB at 1 month
			PL	-	+	+	
25	CoT	Asymptomatic (T1)	AF	+	+	+	
			PL	-	-	-	
26	CoT	Unknown (T3)	PL	-	+	+	Persisting IgG at 1 year of life
27	CoT	Asymptomatic (T3)	PL	-	+	+	Neosynthesized IgG by WB at 3 months of life
28	CoT	Chorioretinitis (T3)	AF	+	+	+	IgM and IgA detection at birth and neosynthesized IgG (WB) at 1 month of life
			PL	-	+	+	
29	CoT	Asymptomatic (T2)	AF	+	+	+	Neosynthesized IgG at 3 month (WB)

			PL	-	-	-	
30	CoT	Asymptomatic (T3)	PL	-	+	-	Neosynthesized IgG/IgM by WB; IgM and IgA detection at birth
31	CoT	Asymptomatic (T2)	AF	-	+	-	DNA detection by REP-529 qPCR in cord blood (B1 not determined)
			PL	-	-	-	
32	CoT	Asymptomatic (T3)	PL	+	+	+	Neosynthesized IgG/IgM by WB; IgM and IgA detection at birth
			CB	-	+	ND	
33	CoT	Asymptomatic (T3)	AF	+	+	+	IgM and IgA detection at birth, neosynthesized IgG by WB during follow-up
			PL	-	+	+	
34	CoT	Unknown (T3)	PL	+	+	ND	Positive prenatal diagnostic in another hospital
35	CoT	Chorioretinitis and intracerebral calcifications (T2)	AF	+	+	+	Persisting IgG at 1 year of life
			PL	-	-	-	
36	CoT	Asymptomatic (T3)	AF	+	+	+	Neosynthesized IgG/IgM by WB; IgM and IgA detection at birth
			PL	-	+	-	
37	CoT	Asymptomatic (T3)	PL	+	+	+	Neosynthesized IgG/IgM by WB; IgM and IgA detection at birth
38	CoT	Asymptomatic (T3)	AF	+	+	+	
			PL	+	+	+	
39	CoT	Unknown (T3)	AF	+	+	+	Positive serological monitoring in another hospital
40	CoT	Asymptomatic (T3)	PL	+	+	+	Positive prenatal diagnostic in another hospital, IgM at birth
41	CoT	Asymptomatic (T3)	PL	-	-	+	IgM and IgA detection at birth and neosynthesized IgG (WB)
42	OT	Uveitis	AH	+	+	ND	
43	OT	Uveitis	AH	+	+	ND	Neosynthesized IgG in AH (WB)
44	OT	Uveitis and chorioretinitis	AH	+	+	ND	
45	OT	Uveitis	AH	+	+	ND	Neosynthesized IgG in AH (WB)
46	OT	Hyalitis, not treated for toxoplasmosis	AH	-	+	ND	

47	OT	Uveitis, HIV + patient. Treated for toxoplasmosis	VF	+	+	ND	Neosynthesized IgG in VF (WB)
48	OT	Uveitis, HIV + patient. Treated for toxoplasmosis	PB	-	+	ND	Serological reactivation (high levels of IgG and IgM)
49	OT	Retinochoroiditis, HIV+ patient. Treated for toxoplasmosis.	PB	+	+	ND	
50	CeT		CSF	-	+	ND	
51	CeT	Neurological symptoms, HIV+ patient	CSF	-	+	ND	
52	CeT	Immunocompromised patient, 5 cerebral lesions on CT scan	CeB	+	+	ND	DNA detection in CSF in another hospital
53	CeT	Heart transplant patient, neurological symptoms	CSF	-	+	ND	IgM detection in serum
54	CeT	Cerebellar syndrome	CSF	-	+	ND	Serological reactivation (high levels of IgG and IgM)
55	CL	Chronic toxoplasmosis, asthenia	LNP	-	+	ND	History of seroconversion (persisting IgM)
56	CL	Chronic toxoplasmosis, asthenia	LNP	-	+	ND	History of seroconversion 6 month before

348 CoT, congenital toxoplasmosis; AF, amniotic fluid; PL, placenta; CB, cord blood; AP, abortion product; T1, first trimester of pregnancy; T2, second trimester
349 of pregnancy; T3, third trimester of pregnancy; OT, ocular toxoplasmosis; AH, aqueous humor; PB, peripheral blood; VF, vitreous fluid
350 CeT, cerebral toxoplasmosis; CSF, cerebro-spinal fluid, CeB, cerebral biopsy
351 CL, chronic lymphadenopathy; LNP, lymph node puncture; ND, not determined ; WB, Western-blot
352

353 Table 2: Relative sensitivity of B1 qPCR on samples tested positive with REP-529 qPCR, according to
354 the type of sample

Sample	B1 qPCR result
	No positive/Total No (%)
Amniotic fluid	18/20 (90)
Placenta	13/28 (46.4)
Abortion product	0/1 (0)
Cord blood	0/5 (0)
Blood	1/2 (50)
Ocular fluids	5/6 (83)
Cerebrospinal fluid	0/4 (0)
Biopsy (cerebral or lymph node)	1/3 (33)
All samples	38/69 (55)

355

356

357 Table 3: Sensitivity of B1 qPCR and REP-529 qPCR for the diagnosis of congenital toxoplasmosis

358 (2003-2013)

Sample	B1 qPCR result	REP-529 qPCR result
	No positive/Total No (%)	No positive/Total No (%)
Prenatal diagnosis (amniotic fluid)	18/20 (90)	20/20 (100%)
Neonatal diagnosis (placenta)	13/35 (37)	28/35 (80%)

359

360

361 Table 4: Mean Cycle threshold (Ct) obtained with B1 qPCR and REP-529 qPCR, according to sample

362 type.

363

Sample	Ct B1 (Mean ± SEM)	Ct Rep 529 (Mean ± SEM)	ΔCt (Mean ± SEM)	P value ^a	P value ^b
Amniotic fluid (n = 18)	34.80 ± 0.58	29.87 ± 0.57	4.93 ± 1.35	0.0002***	<0.0001***
Placenta (n = 12)	35.86 ± 0.57	30.87 ± 0.58	4.98 ± 2.07	0.0002***	<0.0001***
Ocular fluids (n =5)	32.98 ± 2.00	29.84 ± 2.30	3.49 ± 1.1	0.0625	0.3095
All samples (n = 37)	34.51 ± 0.56	29.7 ± 0.53	4.81 ± 0.31	<0.0001***	<0.0001

364 ^a Wilcoxon test; ^b Mann Whitney test

365 ***, p<0.001

366